Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Inclusion Criteria: * Male or female between the ages of 6 and 17 years, inclusive * Children with diagnosed ADHD (as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision \[DSM-IV-TR\] criteria) * Complaint of childhood insomnia as defined by repeated difficulty with sleep initiation or consolidation that occurs despite adequate age, appropriate time, and opportunity for sleep * The sleep disturbance must not be attributable to either the direct physiologic effect of drug abuse or misuse of a prescribed medication. * Subjects should be stabilized on all long-term therapy, including treatment of ADHD, for at least one month prior to study entry. * Subjects, if females of childbearing potential (as determined by the initiation of menses), must have confirmed negative pregnancy test prior to randomization and be using a recognized effective method of birth control (oral, implant, depot or transdermal oestroprogestatives, intrauterine device, double-barrier with spermicide). Abstinence is an acceptable method of birth control for this study. Exclusion Criteria: * Mental retardation * Autistic spectrum disorder * A history of sleep apnea * A history of bipolar disorder, conduct disorder, major depression, or generalized anxiety disorder (not obsessive compulsive disorder), as determined by clinical interview and DSM-IV-TR criteria * Current history of substance abuse/dependence * Known hypersensitivity to zolpidem or previous adverse experience with zolpidem * Pregnant or breast-feeding * Current use of hypnotics, antihistamines, melatonin, herbal products, or other sleep aids